Perbak Capital Partners LLP Lowers Stock Position in QIAGEN N.V. $QGEN

Key Points

• Perbak Capital Partners LLP has reduced its position in QIAGEN N.V. by 56.4%, now holding 14,857 shares valued at approximately $597,000 after selling 19,220 shares in the first quarter.
• Institutional interest in QIAGEN is strong, with 70% of the stock owned by hedge funds and institutional investors, including Graham Capital Management which increased its stake by 92.7% during the same period.
• Analysts have mixed views on QIAGEN, with price targets raised by Bank of America and UBS Group, but overall ratings leaning towards a "Hold" from most analysts.

Perbak Capital Partners LLP trimmed its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 56.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,857 shares of the company's stock after selling 19,220 shares during the quarter. Perbak Capital Partners LLP's holdings in QIAGEN were worth $597,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in QGEN. Exchange Traded Concepts LLC raised its position in shares of QIAGEN by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock valued at $716,000 after buying an additional 395 shares during the period. SVB Wealth LLC acquired a new position in QIAGEN in the 1st quarter valued at about $31,000. Walleye Trading LLC increased its stake in QIAGEN by 14.6% during the first quarter. Walleye Trading LLC now owns 7,367 shares of the company's stock worth $296,000 after purchasing an additional 936 shares during the period. Cetera Investment Advisers increased its stake in QIAGEN by 14.4% during the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after purchasing an additional 1,418 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of QIAGEN by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

QIAGEN Stock Up 1.1%

QIAGEN stock traded up $0.50 during mid-day trading on Friday, hitting $47.54. The company had a trading volume of 939,634 shares, compared to its average volume of 1,332,689. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The business has a fifty day moving average of $48.65 and a 200 day moving average of $44.42. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 28.08, a PEG ratio of 2.51 and a beta of 0.64.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The company's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts expect that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on QGEN. Bank of America upped their target price on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen reiterated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. UBS Group raised their price objective on shares of QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Barclays assumed coverage on shares of QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.